INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 177 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2020. The put-call ratio across all filers is 0.76 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $21,000 | -69.6% | 367 | -78.4% | 0.00% | -66.7% |
| Q2 2021 | $69,000 | +68.3% | 1,700 | +7.5% | 0.00% | 0.0% |
| Q3 2020 | $41,000 | +485.7% | 1,582 | +274.0% | 0.00% | +200.0% |
| Q1 2020 | $7,000 | -73.1% | 423 | -42.5% | 0.00% | -50.0% |
| Q4 2019 | $26,000 | +188.9% | 736 | -35.7% | 0.00% | +100.0% |
| Q3 2019 | $9,000 | -62.5% | 1,145 | -39.0% | 0.00% | -50.0% |
| Q2 2019 | $24,000 | +500.0% | 1,878 | +501.9% | 0.00% | – |
| Q1 2019 | $4,000 | -50.0% | 312 | -57.8% | 0.00% | -100.0% |
| Q4 2018 | $8,000 | +300.0% | 739 | +396.0% | 0.00% | – |
| Q2 2017 | $2,000 | -83.3% | 149 | -80.1% | 0.00% | -100.0% |
| Q1 2017 | $12,000 | -60.0% | 748 | -62.9% | 0.00% | -66.7% |
| Q4 2016 | $30,000 | -69.7% | 2,016 | -43.6% | 0.00% | -66.7% |
| Q1 2016 | $99,000 | – | 3,574 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |